511 related articles for article (PubMed ID: 29371588)
21. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen.
David K; Ollert MW; Vollmert C; Heiligtag S; Eickhoff B; Erttmann R; Bredehorst R; Vogel CW
Cancer Res; 1999 Aug; 59(15):3768-75. PubMed ID: 10446994
[TBL] [Abstract][Full Text] [Related]
22. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
23. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
24. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.
Morandi F; Chiesa S; Bocca P; Millo E; Salis A; Solari M; Pistoia V; Prigione I
Neoplasia; 2006 Oct; 8(10):833-42. PubMed ID: 17032500
[TBL] [Abstract][Full Text] [Related]
25. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
[TBL] [Abstract][Full Text] [Related]
26. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
Decock A; Ongenaert M; Vandesompele J; Speleman F
Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
[TBL] [Abstract][Full Text] [Related]
27.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
28. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
Chen S; Zhou C; Ma X; Gong L
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
30. An overview of neuroblastoma cell lineage phenotypes and
Campos Cogo S; Gradowski Farias da Costa do Nascimento T; de Almeida Brehm Pinhatti F; de França Junior N; Santos Rodrigues B; Cavalli LR; Elifio-Esposito S
Exp Biol Med (Maywood); 2020 Dec; 245(18):1637-1647. PubMed ID: 32787463
[TBL] [Abstract][Full Text] [Related]
31. Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.
Satoh S; Takatori A; Ogura A; Kohashi K; Souzaki R; Kinoshita Y; Taguchi T; Hossain MS; Ohira M; Nakamura Y; Nakagawara A
Sci Rep; 2016 Sep; 6():32682. PubMed ID: 27604320
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.
Jarnjak-Jankovic S; Pettersen RD; Saebøe-Larssen S; Wesenberg F; Olafsen MR; Gaudernack G
Cancer Gene Ther; 2005 Aug; 12(8):699-707. PubMed ID: 15846368
[TBL] [Abstract][Full Text] [Related]
34. Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.
Fest S; Soldati R; Christiansen NM; Zenclussen ML; Kilz J; Berger E; Starke S; Lode HN; Engel C; Zenclussen AC; Christiansen H
Int J Cancer; 2016 Apr; 138(8):2030-42. PubMed ID: 26595750
[TBL] [Abstract][Full Text] [Related]
35. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
36. Role of stemness-related molecules in neuroblastoma.
Kamijo T
Pediatr Res; 2012 Apr; 71(4 Pt 2):511-5. PubMed ID: 22430387
[TBL] [Abstract][Full Text] [Related]
37. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
38. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
Tian X; Zhou D; Chen L; Tian Y; Zhong B; Cao Y; Dong Q; Zhou M; Yan J; Wang Y; Qiu Y; Zhang L; Li Z; Wang H; Wang D; Ying G; Zhao Q
Cell Death Dis; 2018 Jan; 9(2):54. PubMed ID: 29352113
[TBL] [Abstract][Full Text] [Related]
39. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of human neuroblastoma.
Prigione I; Corrias MV; Airoldi I; Raffaghello L; Morandi F; Bocca P; Cocco C; Ferrone S; Pistoia V
Ann N Y Acad Sci; 2004 Dec; 1028():69-80. PubMed ID: 15650233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
